Page 22 - Morphosys News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys Today - Breaking & Trending Today

MorphoSys Cuts FY Monjuvi U.S. Net Product Sales Outlook

MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR, MPSYY.PK) said that it now expects Monjuvi U.S. net product sales for the full year of 2022 to be about US$90 million, compared to the prior guidance ....

Jean Paul Kress , Product Sales , Chief Executive Officer ,

MorphoSys AG: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)Anticipated full year ....

United States , United Kingdom , Kaitlyn Nealy , Thomas Biegi , Julia Neugebauer , Jean Paul Kress , Morphosys Agview , Exchange Commission , Xencor Inc , Drug Administration , Updates Financial Guidance , Product Sales , Chief Executive Officer , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report ,

MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

EQS-News: MorphoSys AG

/ Key word: Change in Forecast

MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

21.10.2022 / 11:41. | October 21, 2022 ....

United States , United Kingdom , Kaitlyn Nealy , Thomas Biegi , Julia Neugebauer , Jean Paul Kress , Exchange Commission , Xencor Inc , Drug Administration , Updates Financial Guidance , Product Sales , Chief Executive Officer , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report , Morphosys Ag Stock Exchange , Press Release , 022 Mor De0006632003 ,

EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 Seite 1

21.10.2022 - EQS-Ad-hoc: MorphoSys AG / Key word(s): Change in Forecast Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 21-Oct-2022 / 11:39 CET/CEST Disclosure of an inside information acc. to Article . Seite 1 ....

Updates Financial Guidance , Product Sales , Qs Adhoc ,

Wie Biogen Idec, Vapiano, MorphoSys, Salzgitter, Baader Bank und Varta AG für Gesprächsstoff sorgten

Wie Biogen Idec Vapiano MorphoSys Salzgitter Baader Bank und Varta AG für Gesprächsstoff sorgten Aktie Symbol SK Perf. Idec BIIB 276.61 39.85% Vapiano VAO 0.099 23.50% MorphoSys MOR 22.23 20.16% VAR1 32.76 -8.08% ....

Christoph Boschan , Vienna Stock Exchange ,